Morgan Stanley analyst Jeffrey Hung resumed coverage of Exelixis with an Equal Weight rating and $21 price target. The firm’s estimates for Cabometyx sales are inline with the consensus. The analyst is looking for additional details ahead of upcoming readouts like CONTACT-02 topline results in the second half of 2023 and COSMIC-313 data in 2023 in order to get more constructive on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>